Table 2.
Crude Hazard Ratios for Predictors of Antiretroviral Therapy-Treated Kaposi's Sarcoma Disease Progression
| HR | 95% CI | p | |
|---|---|---|---|
| Age | 0.96 | 0.90–1.03 | .26 |
| Male | 1.03 | 0.35–3.01 | .95 |
| Smoking | 0.65 | 0.20–2.11 | .48 |
| Alcohol | 2.36 | 0.52–10.75 | .27 |
| Education | |||
| Secondary | 3.03 | 0.77–12 | .27 |
| Tertiary | 2.0 | 0.40 – 9.84 | .41 |
| Multiple KS lesions (>3 lesions) | 1.43 | 0.44–4.61 | .55 |
| Lymphedema | 1.16 | 0.36–3.77 | .80 |
| KS lesion type (nodule) | 3.16 | 0.96–10.42 | .06 |
| Mucous membrane lesions | 1.56 | 0.47–5.12 | .47 |
| More than 4 affected areas | 1.61 | 0.55–4.70 | .39 |
| HIV viral load | 0.99 | 0.99–1 | .16 |
| CD4 count >200 cells/μL | 1.96 | 0.63–6.04 | .24 |
CI, confidence interval; HR, hazard ratio.